CLINICALLY SIGNIFICANT DRUG-INTERACTIONS WITH THE ORAL ANTICOAGULANTS

被引:44
作者
FREEDMAN, MD
OLATIDOYE, AG
机构
[1] Johns Hopkins University School of Medicine, Baltimore, Maryland
[2] Sinai Hospital of Baltimore, Baltimore, Maryland
[3] Department of Internal Medicine, Section of General Internal Medicine, Sinai Hospital of Baltimore, Baltimore, Maryland, 21215
关键词
D O I
10.2165/00002018-199410050-00003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Oral anticoagulants were introduced in the late 1940s and remain widely used today. Indications include prevention of thrombosis associated with atrial fibrillation, structural cardiac diseases and following prosthetic valvular replacement. They have been used for both treatment and prophylaxis of deep venous thrombosis and in efforts to decrease the frequency and rate of second myocardial infarction. These compounds include the coumarin derivatives [dicoumarol (bishydroxycoumarin), phenprocoumon, nicoumalone (acenocoumarol)] and the indanedione derivatives (diphenadione, phenindione. anisindione) which, because of adverse reactions, are largely unavailable. The oral anticoagulants, and warfarin in particular, are highly interactive with other drugs. Mechanisms of those interactions include both pharmacokinetic and pharmacodynamic mechanisms and may result in either hyper- or hypoprothrombinaemia. Because their principal adverse reaction is haemorrhage, and interactions are widespread across many therapeutic specialties, it becomes imperative for the practising physician to be aware of the possibility of interaction whenever these agents are coadministered with other drugs.
引用
收藏
页码:381 / 394
页数:14
相关论文
共 152 条
  • [91] O'Reilly R.A., The steroselective interaction of warfarin and metro-nidazole in man, New England Journal of Medicine, 295, pp. 354-357, (1976)
  • [92] O'Reilly R.A., Ticrynafen-racemic warfarin interactions: hepatotoxic or steroselective?, Clinical Pharmacology and Therapeutics, 32, pp. 356-361, (1982)
  • [93] O'Reilly R.A., Aggeler P.M., Leong L.S., Studies on the coumarin anticoagulant drugs: pharmacodynamics of warfarin in man, Journal of Clinical Investigation, 42, pp. 1542-1551, (1963)
  • [94] O'Reilly R.A., Goulart D.A., Comparative interactions of sulfinpyrazone and phenylbutazone with racemic warfarin alternation in vivo of free fraction of plasma warfarin, Journal Pharmacology and Experimental Therapeutics, 219, pp. 691-694, (1981)
  • [95] O'Reilly R.A., Goulart D.A., Kunze K.L., Neal J., Gibaldi M., Et al., Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects, Clinical Pharmacology and Therapeutics, 51, pp. 656-667, (1992)
  • [96] O'Reilly R.A., Levy G., Kinetics of the anticoagulant bishydroxycoumarin in man, Clinical Pharmacology and Therapeutics, 11, pp. 378-384, (1970)
  • [97] O'Reilly R.A., Motley C.H., Racemic warfarin and trimethoprim-sulfamethoxazole interactions in humans, Annals of Internal Medicine, 91, pp. 34-36, (1979)
  • [98] O'Reilly R.A., Rytand D.A., Resistance to warfarin due to unrecognized vitamin K supplementation, New England Journal of Medicine, 303, pp. 160-161, (1980)
  • [99] O'Reilly R.A., Trager W.F., Motley C.H., Howald W., Interactions of secobarbital with warfarin pseudoracemates, Clinical Pharmacology and Therapeutics, 28, pp. 187-195, (1980)
  • [100] Parr M.D., Record K.E., Griffith G.L., Zeok J.V., Todd E.P., Effect of enterai nutrition on warfarin therapy, Clinical Pharmacology, 1, pp. 274-276, (1982)